CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2019 Earnings Conference Call Transcript

Nov 07, 2019 • 05:00 pm ET

Previous

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2019 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good day, ladies and gentlemen, and welcome to the CytomX Therapeutics Third Quarter 2019 Financial Results Conference Call. [Operator Instructions]

I would now like to introduce your host for today's conference, Christopher Keenan, Vice President of Investor Relations. Chris, you may begin.

Executive
Christopher Keenan

Thank you, Zia. Good afternoon and thank you for joining us. Earlier today we issued a press release that includes a summary of our recent progress and third quarter 2019 financial results. This press release and a recording of this call can be found under the Investors and News section of our website at cytomx.com. With me today are CytomX President, Chief Executive Officer, and Chairman, Dr. Sean McCarthy; CytomX newly appointed Chief Development Officer, Dr. Amy Peterson; and CytomX Vice President of Finance, Robin Knifsend.

During today's call, we will be making forward-looking statements because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov, including our Form 10-Q filed today. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. A webcast of this call will be available on the investor relations page of CytomX website at cytomx.com.

I will now turn the call over to Sean.

Executive
Sean A. McCarthy

Thank you, Chris, and good afternoon, everyone and thanks very much for joining us. It's a pleasure to be here to provide an update on our progress during the third quarter. I'll begin with an overview and some recent highlights and then I'll turn the call over to Amy to review our recent clinical advances in our CX-072 program, I'll then review progress with our partner programs before turning the call over to Robin for the third quarter financial update. I'll then come back and provide some closing comments and open up the call for questions.

So let me start by first introducing a new voice on today's call. Recently we announced the appointment of Dr. Amy Peterson to the new role of Chief Development Officer at CytomX. Amy brings over 20 years of experience in oncology, clinical practice and drug development, having held multiple senior roles, including Chief Medical Officer of immuno-oncology at BeiGene, where she created and led what is today recognized as a globally relevant oncology development organization. Prior to that, Amy was Vice President of Clinical Development at Medivation, where she was responsible for developing XTANDI and TALZENNA in breast cancer.

Amy also held a variety of leadership roles at Genentech, where she worked primarily on early stage oncology assays, targeting multiple major pathways. Here's at CytomX, Amy is charged with oversight of a multidisciplinary team focused on advancing CytomX clinical development activities, and driving value creation and differentiated patient outcomes across the CytomX portfolio. We are delighted to have Amy joining our team at this important time in our